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Summary Imiquimod is an orally active interferon inducer with anti-tumour activity in experimental animals.
In this study the tolerability, toxicity and biological effects of daily oral imiquimod administration were
investigated in 21 patients with refractory cancer. Patients were treated with doses of 25 mg, 50 mg, 100 mg or
200 mg on a projected 112 day course. Only three patients completed the course, all at the 50 mg dose.
Treatment toxicities were dose related and mainly comprised flu-like symptoms, nausea and lymphopenia. Of
the 21 patients, five received dose reductions and in five treatment was discontinued because of treatment-
related toxicity. The biological activity of imiquimod was confirmed by significant and sustained rises in
peripheral blood mononuclear cell (PBMC) 2-5A synthetase (2-5AS) levels at all doses. At 100 mg and 200 mg
these occurred within the first 24 h of administration. Levels of neopterin and fi2-microglobulin (A32M) were
also significantly elevated when assessed after three weeks' treatment. Interferon production was not
demonstrated within the first 24 h of the initial dose but, following repeated doses, ten of the patients
developed detectable serum interferon concentrations with a maximum value of 5600 IU ml recorded.
Administration of imiquimod did not have any significant effect on serum levels of tumour necrosis factor
(TNF) or interleukin 1 (IL-1), nor did it lead to development of detectable levels of antibodies to interferon.
One mixed clinical response was observed after 4 weeks' treatment at 100 mg in a patient with renal cell cancer.
Daily administration of imiquimod causes activation of the interferon production system but at higher doses
results in unacceptable toxicity. Further investigation of imiquimod as an interferon-inducing agent in cancer
patients is suggested at either the lower dose levels or employing alternative dosing schedules.
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Interferon therapy is well established in oncology, playing an
important role in the management of a number of conditions,
including hairy cell leukaemia (Quesada et al., 1984), renal
cell cancer (Horoszewicz and Murphy, 1989) and melanoma
(von Wussow et al., 1988). Current regimens require regular
administration of interferon by subcutaneous injection using
recombinant protein produced in bacteria. Treatment is
associated with significant problems of patient acceptability
and, frequently, a loss of therapeutic efficacy as a result of the
production of neutralising antibodies (Steiss et al., 1988).
Oral interferon-inducing agents offer theoretical advan-
tages of convenience, prolonged action and the avoidance of
immunogenicity. A number of interferon-inducing agents
have been investigated, including polyribonucleotide com-
plexes (Hovanessian et al., 1985), fluorenones (Mayer and
Krueger, 1970), pyrimidones (Nichol et al., 1976) and
anthraquinones (Stringfellow et al., 1979); none have been
shown to induce detectable levels of interferon in man
reliably (Dianzani, 1992). However, it has been shown that
imiquimod [1-(2-methylpropyl)- 1H-imidazo[4,5c]quinolin-4-
amine] (MW 240) can induce interferon production in
cultured human peripheral blood mononuclear cells
(PBMCs) (Weeks and Gibson, 1994). In experimental
animals oral administration of imiquimod leads to interferon
production, with peak activity occurring in mice at doses of
30- 100 mg kg- and biological activity being detected at
doses as low as 3 mg kg-' (Reiter et al., 1994). In murine
tumour models imiquimod has been demonstrated to inhibit
growth of several tumour types (Sidky et al., 1992a) and can
effect complete regression of some transplantable tumours
(Sidky et al., 1990). The inhibition of imiquimod-induced
tumour regression by anti-interferon sera supports an
important role for interferon in mediating the actions of
imiquimod (Sidky et al., 1992a). In addition to the interferon-
inducing actions, imiquimod is postulated to have a direct
anti-tumour action via inhibition of tumour angiogenesis
(Sidky et al., 1992b).
The clinical possibilities of imiquimod's interferon-
inducing actions were first explored in a single-dose safety
trial in healthy volunteers. In this study, detectable
interferon was induced in two out of six subjects at
200 mg; three of six at 250 mg and of 12 at 300 mg
(Wick et al., 1991). The only significant toxicity observed in
this single-dose study were flu-like symptoms that occurred
in the majority of the volunteers. Administration of
imiquimod to cancer patients on a weekly or twice-weekly
schedule has demonstrated biological activity as shown by
significant rises in the interferon-related proteins 2-5AS,
neopterin and 32M, and interferon production in 17 out of
19 patients within 24 h of a single oral dose of 300 mg (Witt
et al., 1993). The toxicity and biological effects of daily oral
imiquimod have not been studied previously, therefore we
have performed a phase I dose-escalation study and present
the results in this paper.
Materials and methods
Patients
Patients with metastatic melanoma or renal cell carcinoma were
entered into this study. Patient eligibility criteria included:
histologically confirmed incurable cancer, performance status
of0- (ECOG), age greater than 18 years, minimum weight of
45 kg without a greater than 5% loss in the preceding 8 weeks,
adequate bone marrow function (WBC>3500 mm-', plate-
lets> 125 000 mm-3, haemoglobin> 10 g dl -' and haemato-
crit >27%), adequate renal function (serum
creatinine < 1.5 mg dl-' and creatinine clearance of
> 50 ml min- ), and liver function (bilirubin < 1.7 mg dl-',
serum glutamic-oxaloacetic transaminase less than twice
normal and albumin >3.0 mg dl-'). Patients had to test
negatively for hepatitis B surface antigen to be included. The
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exclusion criteria included: cytotoxic chemotherapy within 3
weeks (6 weeks for mitomycin C or nitrosureas), immunomo-
dulators, interferon or investigational drugs within 4 weeks,
hormone therapy or glucocorticoids within 2 weeks, require-
ment for palliative radiotherapy, barbiturates, aspirin, non-
steroidal anti-inflammatory agents, anti-convulsants, anti-
arrhythmic agents or cimetidine. Patients with clinically
significant hepatic, renal, neurological, endocrine, gastrointest-
inal illness, severe heart failure, drug or alcohol dependency
were also excluded.
The study was performed at the Royal Marsden Hospital,
London, UK, and written informed consent was obtained
according to the requirements of the institute's ethics
committee.
Treatment
Imiquimod was provided as 25 mg and 100 mg capsules and
taken orally once daily in the morning with 200 ml of water.
Patients were treated at four dose levels: dose level 1, 25 mg
(three patients); dose level 2, 50 mg (eight patients); dose
level 3, 100 mg (seven patients); and dose level 4, 200 mg
(three patients). The duration of treatment was intended to
be for 4 months. Following the first administration, patients
were observed for 24 h in hospital, subsequent doses were
self-administered at home. Dose modifications were as
follows: if grade 3 or 4 toxicity occurred, the treatment
was temporarily discontinued until the toxicity abated then
recommenced with a dose reduction to the next dose level
down; if grade 3 or 4 toxicity recurred, the treatment was
discontinued.
Patient assessment
Vital signs, electrocardiogram, subjective and objective
toxicity, performance status and tumour size were evaluated
pretreatment and at 2-weekly intervals during treatment.
Clinical laboratory test of haematology (full blood count,
prothrombin time), biochemistry (urea, electrolytes and liver
function tests) and urinalysis were performed pretreatment
and at various time points during the study. Toxicity was
assessed weekly and graded according to the WHO criteria;
tumour responses were assessed according to the standard
UICC criteria (Miller et al., 1981).
Biological responses
Serum samples for measurement of interferon, anti-interferon
antibodies, neopterin, /32M, 2-5 AS, TNF and IL-1 were
collected pretreatment and at 1, 4, 6, 12, 18 and 24 h after the
first dose. Subsequently, samples were collected predose and
8 h after dose on day 8 and between days 22 and 49 and days
50 and 112.
Serum interferon concentrations were measured by a
bioassay using human lung carcinoma cells (A549) and
encephalomyocarditis virus (Grossberg et al., 1986), and
calculated by comparison with an international reference
standard. The identity of the interferon as interferon alpha
was confirmed by antibody neutralisation studies. The limit
for detection of interferon in this assay was 10 IU ml-'.
Serum levels of anti-interferon antibodies were determined by
incubating dilutions of patients' serum with a known amount
of interferon and then assaying as described above. A
positive result was taken to be the dilution of serum which
would neutralise ten laboratory units of interferon as
described by the WHO (1983).
Serum concentrations of TNF and IL-1 were measured
by enzyme-linked immunosorbent assay (ELISA), obtained
from Cistron, Pine Brook, NJ, USA. f2M was assayed using
a competitive radioimmunoassay obtained from Pharmacia
Diagnostics, Piscataway, NJ, USA. Serum neopterin was
assayed by a radioimmunoassay employing a kit from DRG
International, Mountainside, NJ, USA. The activity of 2-
5AS in PBMCs was measured by the incorporation of
[3H]ATP into 2',5'-oligoadenylate as described previously
(Witt et al., 1993).
Results
Patient characteristics
Twenty-one patients (nine men, 12 women) with advanced
refractory cancer were treated with once-daily oral imiquimod.
The patients' ages ranged from 30 to 67 years with a median of
55 years. Eleven patients had metastatic melanoma and ten
renal cell cancer. Pretrial therapy comprised surgery in 17
patients, chemotherapy in ten patients, immunotherapy in 12
patients and radiotherapy in four patients. The duration of
treatment with daily imiquimod, dose reductions and reasons
for discontinuation are shown in Table I. Only three (14%)
patients, all in the 50 mg group, completed the treatment. The
mean period of treatment decreased from 62 days at 50 mg to
23 days at 100 mg; ten (48%) ofthe patients withdrew because
of disease progression, and five (24%) withdrew because of
treatment-related toxicity. Three (14%) further patients did not
complete treatment; one patient at 100 mg was lost to follow-
up, one was withdrawn following a myocardial infarction,
which was thought not to be treatment related, and at 200 mg
one patient was withdrawn for a protocol violation after
receiving palliative radiotherapy for bone pain. One dose
reduction occurred in the 50 mg group on day 8 as a result of
grade 3 lymphopenia, which resolved during further treatment
at 25 mg. At 100 mg, three dose reductions occurred between
days 8 and 22; all had grade 3 flu-like symptoms, with two
having concurrent grade 3 leucopenia. In the 200 mg group,
one patient had a dose reduction to 100 mg at day 23 for grade
3 leucopenia.
Efficacy
In the 50 mg dose group, a mixed response was observed in a
patient with renal cell cancer and pulmonary metastases.
After 1 month of treatment, a 25% reduction in the diameter
of the pulmonary metastases was observed, which was
Table I Dose and duration of daily treatment with imiquimod
Initial treatment
Dose No. of Mean duration Reason for discontinuation
(mg) patients (range) PD Toxicity Other Treatment completed
25 3 40 3 - -
(22-50)
50 8 62 3 2 - 3
(8-113)
100 7 23 3 2 2 -
(8-56)
200 3 13 1 1 1
(8-23)
For the first incidence of grade 3 or 4 toxicity a dose reduction was employed, for continuing toxicity
treatment was discontinued. PD, progressive disease.Oral imiquimod: phase I daily administration
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sustained for 8 months. However, while the pulmonary
metastases decreased in size, the patient's hilar and
paratracheal lymphadenopathy continued to progress slowly.
Toxicity
Administration of imiquimod was associated with sustained
dose-related haematological toxicity as shown in Table II.
At 25 mg no significant leucopenia occurred, but at 50 mg
and above grade 3 or 4 lymphopenia occurred in almost
50% of the patients. Despite the frequent incidence of
lymphopenia, reduction in the total white cell count to that
of grade 2 or greater leucopenia was recorded on only three
occasions. These were at days 8 and 22 in two 100 mg
patients and on day 8 for a 200 mg patient. Doses of
100 mg and 200 mg were associated with grade 3 or 4
anaemia in 80% of the patients assessed on day 22. There
was only a minimal effect on platelet count across all the
dose groups with one single transient episode of grade 1
toxicity, which was recorded in the 50 mg treatment group.
Despite the haematological toxicities, there were no episodes
Table II Haematological toxicity of
(WHO >grade2)
daily imiquimod
Dose Days 8-21 Days 22-49 Days 50-112
25mg
Lymphopenia 0/3 0/3
Anaemia 1/3 0/3
50mg
Lymphopenia 2/8 2/5 2/4
Anaemia 0/8 1/5 1/4
100mg
Lymphopenia 2/7+ 2/4+ 0/3
Anaemia 3/7 3/4 1/3
200mg
Lymphopenia 1/3+ 0/1 0/1
Anaemia 2/3 1/1 0/1
The number of patients with grade 2 or greater toxicity is shown
compared with the number of patients present at that dose and
assessment point. +One patient also had grade2 leucopenia.
of sepsis, opportunistic infections or symptomatic anaemia
requiring transfusion.
The non-haematological toxicities of imiquimod are
demonstrated in Table III. The toxicities were dose related
with no events reported for the 25 mg group. At 50 mg and
higher doses, flu-like symptoms were reported in 13/18 (72%)
of patients, and nausea and vomiting in 7/18 (39%) of
patients. These symptoms developed before the first toxicity
assessment at 1 week and persisted throughout the course of
treatment. At 100 mg and 200 mg, hepatic or renal
impairment was recorded in three patients; these abnormal-
ities returned to normal in two of the patients on cessation of
therapy. No consistent changes were recorded in temperature,
pulse rate, blood pressure, respiratory rate or electrocardio-
gram (ECG).
Biological responses
The effects of daily imiquimod administration on interferon
induction are demonstrated in Table IV. Before the
introduction of treatment, interferon levels in all 21 patients
were below the level of detection (10 IU ml-'). In the first
24 h after imiquimod administration there was no detectable
interferon production in any dosing group. In the 25 mg
group there was no detectable interferon production at any
point during the trial. At 50 mg two patients first recorded
detectable interferon levels at the day 8 after dose
assessment with values of 244-344 IU ml-'. Neither of
these patients remained in the trial for the later assessments;
however, by day 22 two other patients in the 50 mg
treatment group had detectable levels (67-122 IU ml-')
Table III Non-haematological toxicity of daily imiquimod
25mg 50mg 100mg 200mg
n=3 n=8 n=7 n=3
Flu-like symptoms 0 5 6 2
Vomiting 0 2 4 1
Hepatic impairment 0 0 1 1
Renal impairment 0 0 1 0
Phlebitis 0 1 0 0
Table IV Induction of interferon production during imiquimod treatment
Dose Day I Day8 Day22 Day56
(mg) Oh 24h Oh 8h Oh 8h Oh 8h
50 0/8 0/8 0/6 2/6 0/5 2/5 0/4 3/4
- - - (244-344) - (67-122) - (36-493)
100 0/7 0/7 1/6 3/6 1/3 1/3 0/2 1/2
- - (1862) (95-2160) (465) (5600) - (525)
The ratios demonstrate the number ofpatients with detectable levels (> 10IUml-') from the total number ofpatients tested pre and post dose on
the sampling days. The range ofvalues is given in parenthesis.
Table V Changes in interferon related proteins
Imiquimod 25mg 50mg 100mg
dose Oh 24h 22days Oh 24h 22days Oh 24h 22days
(n =3) (n =3) (n =2) (n =8) (n =8) (n =6) (n = 7) (n =4) (n =4)
f2M (mgml-1)
2.34 2.15 3.15 2.60 2.78 3.34 2.62 2.77 3.99
(1.7-2.9) (1.7-2.6) (1.7-4.6) (2.1-3.3) (2.2-4.5) (2.4-4.1) (1.8-4.1) (2.0-4.4) (2.8-5.3)
Neopterin
(nmol 11)
4.45 3.95 8.32 11.8 13.1 21.3 13.6 14.9 41.2
(2.3-6.0) (3.6-4.2) (3.4- 12.2) (6.2-21.0) (7.3 -21.2) (4.3-63.4) (8.4- 19.5) (9.5- 19.9) (23.6-68.9)
2-5AS (SA)
17.86 16.03 97.1 18.1 17.25 82.3 15.3 44.1 137.0
(5.3-42.1) (4.6-26.9) (12.3- 181) (1.9-54.4) (5.0-45.2) (2.2-273) (1.0-40.8) (4.3- 156) (21.1 -252)
Mean values are given with range in parenthesis.Oral imiquimod: phase I daily administration
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for the first time, which remained elevated (11 -
493 IU ml-') during the remainder of their time on
treatment, with, in total, 92 and 112 days' treatment
completed respectively. At day 56, another 50 mg patient
recorded his first detectable level (60 IU ml-'). In the
100 mg group, one patient had a level of 1862 IU ml-'
before the day 8 dose. Eight hours after the day 8 dose, two
other patients recorded positive results with levels ranging
up to 2160 IU ml-'. Of these three patients, two continued
to record elevated levels of interferon when tested at later
points in the trial. The highest interferon concentration
recorded of 5600 IU ml-' occurred 8 h after the day 22
100 mg dose. In the 200 mg group, only one patient
remained on treatment at the day 8 assessment; at this
point a value of 25 IU ml-' was recorded.
The effects of imiquimod on the induction of interferon-
associated proteins is shown in Table V. Serum levels of
132M did not show any changes within the first 24 h, but
when assessed after 22 days' treatment, rises of > 1.5-fold
over pretreatment levels were seen in one out of two patients
at 25 mg, two out of seven patients at 50 mg, two out of
four patients at 100 mg and in the only remaining patient at
200 mg. Similarly, neopterin levels did not change signifi-
cantly after 24 h but after 22 days' administration increases
of >2-fold over pretreatment levels were seen in one out of
two patients at 25 mg, two out of seven patients at 50 mg,
three out of four patients at 100 mg and in the single
200 mg patient assayed. 2-5AS levels are the most sensitive
indicator of induction of the interferon production system
and, when assayed at 24 h after the first dose, rises of >2-
fold were recorded in one out of three patients at 25 mg,
two out of seven patients at 50 mg, three out of six patients
at 100 mg and in the only 200 mg patient. When assayed at
22 days, 12 out of a total of 13 patients exhibited more than
2-fold rises in 2-5AS, the sole exception being in the 50 mg
dose group. The patient who recorded a disease response did
not demonstrate detectable levels of interferon during
treatment.
Other biological actions
There were no significant changes in levels of TNF or IL-1 at
any point in the treatment in any of the patients. Antibodies
to interferon were not recorded in any patients before
treatment or at discontinuation. There was no apparent
association between toxicity and interferon levels or with the
levels of the other interferon-related proteins.
Discussion
It is unclear if the linear dose-response relationship that
exists for conventional anti-cancer drugs applies to the
biological response modifiers. It is possible for these agents
that a bell-shaped relationship exists or that a cyclical
approach to drug levels or the use of biological agents in
combinations may increase efficacy (Creekmore et al., 1991).
The problems associated with subcutaneous administration
of interferon, of patient acceptability and immunogenicity,
mean that an orally active interferon inducer would have
significant advantages for clinical use. Imiquimod has
already been demonstrated to induce interferon production
in experimental animals (Sidky et al., 1992), healthy
volunteers (Wick et al., 1991) and in cancer patients using
weekly or twice-weekly dosing schedules (Witt et al., 1993).
In this study of daily imiquimod, dose-limiting toxicity
occurred in 10 of the 21 patients, requiring either dose
reduction or discontinuation. In keeping with previous
studies using once or twice-weekly imiquimod dosing, the
main toxicities observed included flu-like symptoms and
nausea and vomiting. With daily imiquimod administration,
grade 3 or 4 lymphopenia was seen in 40% of patients
receiving 50 mg or more; however, the clinical significance of
this degree of lymphopenia in the absence of neutropenia is
uncertain. These characteristics, including the dose relation-
ship of the toxicity of imiquimod, are similar to those seen
with other clinically tested interferon-inducing agents,
particularly bropirimine (Rios et al., 1986), and probably
reflect similar effects on interferon induction.
The biological activity of imiquimod was demonstrated
by the significant rises in 2-5AS levels that occurred in 85%
of the patients assayed at day 22. Higher drug doses were
associated with earlier rises and greater peak levels; in the
25 mg and 50 mg groups there were no changes within the
first 24 h, but at 100 mg there was a 2.5-fold increase at this
time. #2M and neopterin levels also demonstrated a similar
pattern of dose- and time-related increases, with the 100 mg
group showing 1.5-fold and 3-fold rises, respectively, at day
22. Despite the evidence for induction of the interferon
system at all dose levels, only ten patients recorded
detectable levels of systemic interferon. The time taken to
produce detectable levels initially was variable ranging from
day 8 to day 56; however, the infrequent sampling points do
not allow accurate identification of the actual first date of
detectable levels. However, once produced, the levels
remained elevated throughout the remainder of treatment
in all but one patient. This finding argues against the
development of hyporesponsiveness, which occurred in the
murine trials, although this was seen at much higher dose
levels (30 mg kg-'). One mixed clinical response was seen in
the trial, which occurred in a patient with renal cell
carcinoma after 4 weeks' treatment. However, in this
patient there was no systemic interferon detected.
Overall, these results show that imiquimod can achieve
some of the desired actions of an oral interferon-inducing
agent. Low-dose (25 mg) treatment was well tolerated, with
no significant toxicity and, while not producing systemically
detectable interferon production, was demonstrated to be
immunologically active by the increases in f2M, neopterin
and 2-SAS. Higher doses of 50 mg and above showed almost
uniform immunological activation and production of
interferon in more than 50% of patients, but were associated
with significant dose-limiting toxicity. As expected, imiqui-
mod as an inducer of endogenous interferon did not lead to
the formation of autoantibodies to interferon.
In clinical trials with the oral interferon-inducing agent,
bropirimine, low-level activation of the interferon system,
even in the absence of detectable interferon production, was
shown to produce some clinical responses in bladder cancer
(Rios et al., 1986; Sarosdy et al., 1992). Therefore, it is
possible that imiquimod administered at low doses may
develop a role in adjuvant therapy or in long-term anti-
cancer treatments. Before this, the optimum dosing regimen
needs to be defined, with further investigations of daily
doses of 25-50 mg and the use of variable dosing regimens.
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